|
Newborn Screening Federal Partners Committee
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, HRSA
|
NICHD, NHGRI, NLM
|
The federal members of the Advisory Committee on Heritable Disorders in Newborns and Children meet monthly to share information about newborn screening activities.
|
|
NGSP (formerly the National Glycohemoglobin Standardization Program)
|
Resource Development
|
CDC
|
NIDDK
|
The purpose of the NGSP (formerly the National Glycohemoglobin Standardization Program) is to standardize Hemoglobin A1c test results to those of the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), which established the direct relationships between HbA1c levels and outcome risks in patients with diabetes.
|
|
NHANES 2011-14 Accelerometer Data
|
Health Survey
|
CDC
|
NCI, NIA, NIDDK, NHLBI, OD/DPCPSI/OBSSR, ODP, OD/DPCPSI/ORWH
|
Led by NCI, NIH supported inclusion of accelerometer-based devices in NHANES 2011-14. NCI supported data preparation for release and quality control checking pre-release. Summary data will be publicly available at day/hour/minute levels, as well as 80Hz "raw" data for select users.
Data are released. Analyses are ongoing.
|
|
NIA IMPACT Collaboratory Transforming Dementia Care
|
Research Initiative
|
CDC
|
NIA
|
The mission of the IMbedded Pragmatic Alzheimers disease (AD) and AD Related Dementias (AD/ADRD) Clinical Trials (IMPACT) Collaboratory is to build the nation’s capacity to conduct pragmatic clinical trials of interventions embedded within health care systems for people living with dementia and their care partners.
The IMPACT Collaboratory accomplishes this mission by: developing and disseminating best practice research methods; supporting the design and conduct of pragmatic trials, including pilot studies; building investigator capacity through training and knowledge generation; catalyzing collaboration among stakeholders, healthcare providers, and investigators; and ensuring the research includes culturally-tailored interventions and people from diverse and under-represented backgrounds.
|
|
NIAID-CDC Joint US Partnership Implementing TB Elimination Research (JUPITER)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID
|
Through bi-weekly teleconferences, the Joint US Partnership Implementing TB Elimination Research (JUPITER) facilitates cooperation, communication, and collaboration on tuberculosis between the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC). This approach helps ensure that Federal activities are coordinated and not duplicated, and stimulates collaborations where appropriate.
|
|
NIAID/Armed Forces Radiobiology Research Institute (AFRRI) Research Coordination Team (RCT)
|
Committee, Work group, Advisory group, or Task Force
|
ASPR
|
NIAID
|
The Research Coordinating Team (RCT) has been successfully reestablished and will continue to meet quarterly in 2021. The purpose of the RCT is to discuss progress, resolve any concerns and to explore new areas of research to be conducted under the IAA.
|
|
NIAID/CDC Dual Use Research of Concern (DURC) Risk Mitigation Reviews
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID
|
The Centers for Disease Control and Prevention (CDC) Division of Select Agents and Toxins Division will provide technical assistance in evaluating the sufficiency of the biosecurity and/or biosafety measures incorporated into risk mitigation plans received from institutions, and cross-check risk mitigation plans and research conducted using select agents and toxins against information in the Federal Select Agent Program (FSAP) database.
|
|
NIAID/FDA/BARDA Meeting on Cutaneous Radiation Injuries
|
Meeting/ Workshop
|
BARDA, FDA
|
NIAID, NIGMS
|
A meeting was held May 6-7, 2019. The purpose of this meeting was to bring together medical countermeasures stakeholders such as academicians, industry, and funding and regulatory agencies to consider animal models and endpoints for radiation injuries to the skin
|
|
NIAID/FDA/BARDA Meeting on Radiation-Induced Lung Injuries
|
Meeting/ Workshop
|
FDA, ASPR
|
NIAID
|
A meeting was held March 20-21, 2019. The purpose of this meeting was to bring together medical countermeasures stakeholders such as academicians, industry, and funding and regulatory agencies to consider animal models and endpoints for radiation injuries to the lung.
|
|
NIAID/NASA Medical Countermeasures Working Group
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, FDA
|
NIAID, NCI, NHLBI
|
The purpose of this Working Group (WG) is to bring together experts in radiation countermeasures to look for complementary areas of research across agencies in the following areas: medical countermeasure selection, repurposing, research strategies, and animal models for select endpoints.
|